Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1995 4
1996 7
1997 3
1998 5
1999 6
2000 3
2001 3
2002 4
2003 5
2004 6
2005 4
2006 6
2007 5
2008 6
2009 1
2010 3
2011 5
2012 4
2013 2
2014 3
2015 4
2016 6
2017 9
2018 7
2019 7
2020 9
2021 9
2022 8
2023 11
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, Bjurlin M, Cher ML, Clark W, Cowan BE, David R, Goldfischer E, Guru K, Jalkut MW, Kaffenberger SD, Kaminetsky J, Katz AE, Koo AS, Sexton WJ, Tikhonenkov SN, Trabulsi EJ, Trainer AF, Spilman P, Huang M, Bhar P, Taha SA, Sender L, Reddy S, Soon-Shiong P. Chamie K, et al. Among authors: cher ml. NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10. NEJM Evid. 2023. PMID: 38320011
Reply by Authors.
Paudel R, Madan R, Qi J, Ferrante S, Cher ML, Lane BR, George AK, Semerjian A, Ginsburg KB; Michigan Urological Surgery Improvement Collaborative. Paudel R, et al. Among authors: cher ml. J Urol. 2023 Jan;209(1):178-179. doi: 10.1097/JU.0000000000003012.02. Epub 2022 Oct 21. J Urol. 2023. PMID: 36268990 No abstract available.
Reply by Authors.
Ginsburg KB, Curtis GL, Timar RE, George AK, Cher ML. Ginsburg KB, et al. Among authors: cher ml. J Urol. 2020 Oct;204(4):845. doi: 10.1097/JU.0000000000001193. Epub 2020 Jul 1. J Urol. 2020. PMID: 32609581 No abstract available.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Editorial Commentary.
Lane BR, Cher ML. Lane BR, et al. Among authors: cher ml. Urol Pract. 2016 Sep;3(5):377. doi: 10.1016/j.urpr.2015.10.012. Epub 2016 Jun 6. Urol Pract. 2016. PMID: 37592575 No abstract available.
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.
Morgan TM, Daignault-Newton S, Spratt DE, Dunn RL, Singhal U, Okoth LA, Feng FY, Johnson AM, Lane BR, Linsell S, Ghani KR, Montie JE, Mehra R, Hollenbeck BK, Maatman T, Wojno K, Burks FN, Bekong D, Curry J, Rodriguez P, Kleer E, Sarle R, Miller DC, Cher ML. Morgan TM, et al. Among authors: cher ml. Eur Urol. 2025 Feb;87(2):228-237. doi: 10.1016/j.eururo.2024.09.011. Epub 2024 Oct 8. Eur Urol. 2025. PMID: 39379238 Clinical Trial.
A Roadmap for Improving the Management of Favorable Risk Prostate Cancer.
Auffenberg GB, Lane BR, Linsell S, Brachulis A, Ye Z, Rakic N, Montie J, Miller DC, Cher ML. Auffenberg GB, et al. Among authors: cher ml. J Urol. 2017 Dec;198(6):1220-1222. doi: 10.1016/j.juro.2017.07.085. Epub 2017 Aug 3. J Urol. 2017. PMID: 28782516 No abstract available.
144 results